[go: up one dir, main page]

HN2009001607A - Derivados de ciclohehexil- amida- del acido aril-carboxilico - Google Patents

Derivados de ciclohehexil- amida- del acido aril-carboxilico

Info

Publication number
HN2009001607A
HN2009001607A HN2009001607A HN2009001607A HN2009001607A HN 2009001607 A HN2009001607 A HN 2009001607A HN 2009001607 A HN2009001607 A HN 2009001607A HN 2009001607 A HN2009001607 A HN 2009001607A HN 2009001607 A HN2009001607 A HN 2009001607A
Authority
HN
Honduras
Prior art keywords
ciclohehexil
amida
aril
derivatives
carboxilic acid
Prior art date
Application number
HN2009001607A
Other languages
English (en)
Inventor
Rene Hersperger
Philipp Janser
Wolfgang Mailtz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HN2009001607A publication Critical patent/HN2009001607A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

EN COMPUESTO DE LA FORMILA O UNA SAL FARMACEUTICAMENTE ACEPTABLE O ESTER DE PRO-FARMACOS DEL MISMO... VER FORMULA EN EXPEDIENTE.... EN DONDE LAS VARIANTES R Y X SE DEFINE EN LA MEMORIA DESCRIPTIVA
HN2009001607A 2007-02-19 2009-08-18 Derivados de ciclohehexil- amida- del acido aril-carboxilico HN2009001607A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07102622 2007-02-19

Publications (1)

Publication Number Publication Date
HN2009001607A true HN2009001607A (es) 2011-11-23

Family

ID=38058317

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2009001607A HN2009001607A (es) 2007-02-19 2009-08-18 Derivados de ciclohehexil- amida- del acido aril-carboxilico

Country Status (35)

Country Link
US (1) US8354431B2 (es)
EP (1) EP2125782B1 (es)
JP (1) JP5180234B2 (es)
KR (1) KR101070984B1 (es)
CN (1) CN101605781B (es)
AR (1) AR065369A1 (es)
AT (1) ATE518854T1 (es)
AU (1) AU2008219317B2 (es)
BR (1) BRPI0807625A2 (es)
CA (1) CA2677565C (es)
CL (1) CL2008000497A1 (es)
CR (1) CR10957A (es)
CY (1) CY1111984T1 (es)
DK (1) DK2125782T3 (es)
EA (1) EA017000B1 (es)
EC (1) ECSP099584A (es)
ES (1) ES2371126T3 (es)
GT (1) GT200900226A (es)
HN (1) HN2009001607A (es)
HR (1) HRP20110793T1 (es)
IL (1) IL200191A (es)
MA (1) MA31206B1 (es)
MX (1) MX2009008145A (es)
MY (1) MY147487A (es)
NZ (1) NZ578663A (es)
PE (1) PE20081785A1 (es)
PL (1) PL2125782T3 (es)
PT (1) PT2125782E (es)
RS (1) RS51986B (es)
SI (1) SI2125782T1 (es)
TN (1) TN2009000345A1 (es)
TW (1) TW200848038A (es)
UA (1) UA97389C2 (es)
WO (1) WO2008101905A1 (es)
ZA (1) ZA200905160B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
MX2023006056A (es) 2020-11-25 2023-06-06 Akagera Medicines Inc Nanoparticulas lipidicas para suministro de acidos nucleicos y metodos de uso de las mismas.
EP4531819A2 (en) 2022-05-25 2025-04-09 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132987A (en) 1994-01-13 2000-10-17 The Regents Of The University Of California Recombinant mammalian monocyte chemotactic protein-1 (MCP-1) receptors (MCP-1R, CCR-2)
DK1482042T3 (da) 1996-03-01 2009-06-15 Euroscreen Sa Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren
WO1997045543A2 (en) * 1996-05-28 1997-12-04 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Cc chemokine receptor 5, antibodies thereto, transgenic animals
US6388055B1 (en) 1996-10-03 2002-05-14 Smithkline Beecham Corporation Mouse CC-CKR5 receptor polypeptide
AR008331A1 (es) 1997-01-23 1999-12-29 Smithkline Beecham Corp Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen
WO1999032100A2 (en) * 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
WO2000037455A1 (en) * 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5
WO2001051077A1 (en) 2000-01-14 2001-07-19 The Government Of The United States Of Americarep Resented By The Secretary, Department Of Health And Human Services Methods of regulating il-12 production by administering ccr5 agonists and antagonists
EP1317284A2 (en) 2000-09-08 2003-06-11 Micromet AG Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
WO2003030897A1 (en) 2001-10-03 2003-04-17 Ucb, S.A. Pyrrolidinone derivatives
JPWO2004054616A1 (ja) * 2002-12-13 2006-04-20 小野薬品工業株式会社 ケモカイン受容体の強結合部位に結合するアンタゴニストおよびアゴニスト
JPWO2004098638A1 (ja) * 2003-05-06 2006-07-13 小野薬品工業株式会社 エフェクター細胞機能阻害剤
US7943130B2 (en) * 2003-12-11 2011-05-17 Yale University Methods and compositions relating to CCR5 antagonist, IFN-γ and IL-13 induced inflammation
UA82917C2 (en) * 2003-12-18 2008-05-26 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptor
GB0403038D0 (en) * 2004-02-11 2004-03-17 Novartis Ag Organic compounds
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
KR100837019B1 (ko) * 2004-05-11 2008-06-10 인사이트 코포레이션 케모카인 수용체 조절제로서3-(4-헤테로아릴사이클로헥실아미노)사이클로펜탄카복스아마이드
GB0412468D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
US20070149557A1 (en) 2005-11-21 2007-06-28 Amgen Inc. CXCR3 antagonists
GB0525957D0 (en) 2005-12-21 2006-02-01 Astrazeneca Ab Methods
RU2420284C2 (ru) 2006-06-12 2011-06-10 Пфайзер Продактс Инк. Антагонист ccr5 для усиления иммуновосстановительной терапии и лечения оппортунистической инфекции у пациентов с вич
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
WO2008060783A2 (en) 2006-10-05 2008-05-22 Centocor Ortho Biotech Inc. Ccr2 antagonists for treatment of fibrosis
TW200831497A (en) 2006-10-12 2008-08-01 Epix Delaware Inc Carboxamide compounds and their use
US8754107B2 (en) 2006-11-17 2014-06-17 Abbvie Inc. Aminopyrrolidines as chemokine receptor antagonists
WO2008099278A2 (en) 2007-02-15 2008-08-21 Pfizer Limited Pharmaceutical compositions and methods for ccr5 antagonists
EP2150817A4 (en) 2007-04-30 2011-09-07 Progenics Pharm Inc PROCEDURE FOR REDUCING VIRUS LOAD IN HIV-1 INFECTED PATIENTS

Also Published As

Publication number Publication date
WO2008101905A1 (en) 2008-08-28
RS51986B (sr) 2012-02-29
NZ578663A (en) 2011-01-28
AR065369A1 (es) 2009-06-03
ECSP099584A (es) 2009-09-29
IL200191A0 (en) 2010-04-15
HRP20110793T1 (hr) 2011-11-30
CN101605781B (zh) 2014-08-13
HK1138836A1 (en) 2010-09-03
CL2008000497A1 (es) 2008-08-29
US8354431B2 (en) 2013-01-15
KR101070984B1 (ko) 2011-10-06
JP5180234B2 (ja) 2013-04-10
EA200901085A1 (ru) 2010-02-26
PL2125782T3 (pl) 2011-12-30
ZA200905160B (en) 2010-05-26
MY147487A (en) 2012-12-14
EP2125782B1 (en) 2011-08-03
AU2008219317A1 (en) 2008-08-28
TW200848038A (en) 2008-12-16
CR10957A (es) 2009-09-01
US20100016361A1 (en) 2010-01-21
UA97389C2 (en) 2012-02-10
CA2677565C (en) 2014-11-18
ES2371126T3 (es) 2011-12-27
MA31206B1 (fr) 2010-02-01
BRPI0807625A2 (pt) 2014-05-27
KR20090103943A (ko) 2009-10-01
JP2010519187A (ja) 2010-06-03
IL200191A (en) 2013-12-31
PE20081785A1 (es) 2009-01-12
CN101605781A (zh) 2009-12-16
ATE518854T1 (de) 2011-08-15
MX2009008145A (es) 2009-08-12
SI2125782T1 (sl) 2011-12-30
AU2008219317B2 (en) 2011-09-08
PT2125782E (pt) 2011-11-17
GT200900226A (es) 2010-07-02
CY1111984T1 (el) 2015-11-04
EP2125782A1 (en) 2009-12-02
TN2009000345A1 (en) 2010-12-31
DK2125782T3 (da) 2011-11-21
CA2677565A1 (en) 2008-08-28
EA017000B1 (ru) 2012-09-28

Similar Documents

Publication Publication Date Title
NL300871I2 (nl) ixazomib en farmaceutisch aanvaardbare zouten en esters daarvan, zoals ixazomibcitraat
NO2019027I1 (no) kobicistat eller et farmasøytisk akseptabelt salt derav
CY2013023I2 (el) Φαρμακο για την υπερδραστηρια ουροδοχο κυστη περιλαμβανον παραγωγο ανιλιδιου οξικου οξεοσως το ενεργο συστατικο
NO2016014I2 (no) ceritinib eller farmasøytisk akseptable salter derav
EP2394999A4 (en) AMINO PYRAZINE DERIVATIVE AND MEDICINE
DE602007011902D1 (de) Spiroindolinon-derivate
DE602007002909D1 (de) Geschoss zur verabreichung eines medikaments
EP2178891B8 (de) Phosphonigsäuren, -salze und -ester, verfahren zu deren herstellung und ihre verwendung
EP2281103A4 (en) SYSTEM AND METHOD FOR UNDERWATER DRILLING
EP1849773A4 (en) PYRIDYL (NON-AROMATED NITROGENATED HETEROCYCLIC 1-CARBOXYLATESTER) DERIVATIVE
MX2009003081A (es) Derivados de pirrola utiles para el tratamiento de enfermedades mediadas por citoquinas.
FR2898356B1 (fr) Diesters d'acides carboxylique ramifies
NO20080554L (no) Pyrazolonderivater
FR2898636B1 (fr) Structure de queue-d'aronde de soufflante.
DOP2012000050A (es) Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina
NL1029250A1 (nl) Benzimidazoloncarbonzuurderivaten.
EP2315757A4 (en) PREPARATION OF HYDROXYMETHYLFURFUAL
DOP2009000106A (es) Compuestos de pirazol y triazol sustituídos como inhibidores de ksp
NO20084543L (no) Benzimidazolderivater
FR2906530B1 (fr) Procede de synthese d'esters d'estolides.
HN2009001607A (es) Derivados de ciclohehexil- amida- del acido aril-carboxilico
ECSP066693A (es) Derivados de bencimidazol
EP2033650A4 (en) INHIBITOR OF EXPRESSION OF AP-1 NUCLEAR TRANSCRIPTION FACTOR, AND PHARMACEUTICAL OR OTHER PRODUCTS USING THE INHIBITOR
WO2009011901A3 (en) Methods for promoting wakefulness
WO2008015695A3 (en) Inclusion complex of olopatadine and cyclodextrin